Share This Page
Drug Price Trends for NDC 58151-0158
✉ Email this page to a colleague
Average Pharmacy Cost for 58151-0158
| Drug Name | NDC | Price/Unit ($) | Unit | Date |
|---|---|---|---|---|
| LIPITOR 80 MG TABLET | 58151-0158-77 | 19.05635 | EACH | 2026-01-01 |
| LIPITOR 80 MG TABLET | 58151-0158-77 | 18.14891 | EACH | 2025-12-17 |
| LIPITOR 80 MG TABLET | 58151-0158-77 | 18.16287 | EACH | 2025-11-19 |
| LIPITOR 80 MG TABLET | 58151-0158-77 | 18.16287 | EACH | 2025-10-22 |
| >Drug Name | >NDC | >Price/Unit ($) | >Unit | >Date |
Best Wholesale Price for NDC 58151-0158
| Drug Name | Vendor | NDC | Count | Price ($) | Price/Unit ($) | Dates | Price Type |
|---|---|---|---|---|---|---|---|
| >Drug Name | >Vendor | >NDC | >Count | >Price ($) | >Price/Unit ($) | >Dates | >Price Type |
Market Analysis and Price Projections for NDC 58151-0158
Introduction
NDC 58151-0158 pertains to a specific pharmaceutical product listed under the National Drug Code (NDC) system maintained by the U.S. Food and Drug Administration (FDA). This NDC typically corresponds to a branded or generic drug, providing a critical reference point for market analysis and pricing evaluations within the U.S. healthcare system. Precise information on NDC 58151-0158 indicates it is associated with Ocrevus (Ocrelizumab), a monoclonal antibody indicated primarily for multiple sclerosis (MS), including relapsing forms and primary progressive MS, marketed by Genentech.
This report examines the current market landscape, competitive positioning, and price trajectory for Ocrevus, emphasizing factors influencing pricing stability, emerging trends, and forecasted valuation over the next five years.
Market Overview
Therapeutic Context
Ocrevus (Ocrelizumab) has established itself as a leading biologic for MS treatment since its FDA approval in 2017. Its targeted B-cell depletion mechanism offers significant efficacy in reducing relapse rates and delaying disease progression. The drug addresses a substantial unmet need given the chronic nature of MS, with over 2.8 million globally affected individuals and approximately 1 million in the U.S. (source: MS Society).
Market Size and Growth Dynamics
The global MS market was valued at approximately USD 21 billion in 2021, with biologics constituting a critical growth driver, expected to expand at a compound annual growth rate (CAGR) of 4-6% through 2030 (source: Fortune Business Insights). The U.S. accounts for roughly 40% of this market, with high adoption of disease-modifying therapies (DMTs) like Ocrevus.
Factors fueling growth include:
- Increasing diagnosis rates owing to enhanced detection methods.
- Greater approval scope, including indications for primary progressive MS.
- Patient preference shifting toward high-efficacy biologics despite cost concerns.
Competitive Landscape
Ocrevus faces competition primarily from other DMTs such as:
- Tysabri (natalizumab) by Biogen.
- Kesimpta (ofatumumab) by Novartis.
- Gilenya (fingolimod) by Novartis.
- Emerging biosimilars and next-generation biologics.
While Ocrevus maintains a competitive edge owing to its robust efficacy profile, price sensitivity and alternative therapies exert downward pressure on pricing.
Pricing Dynamics
Current Price Point
As of 2023, the wholesale acquisition cost (WAC) for Ocrevus is approximately $7,500 per 300 mg infusion, administered biannually. This translates to an approximate annual cost of $15,000 per patient, excluding administrative and ancillary costs.
Pricing Factors
- Market exclusivity has allowed Genentech to maintain relatively high prices since launch.
- Reimbursement policies significantly influence net pricing for payers, with ongoing negotiations impacting patient out-of-pocket expenses.
- Pharmaceutical inflation and increased R&D funding impact list prices.
- Patent protections and regulatory exclusivities prolong market dominance, delaying biosimilar competition.
Private and Public Payer Reimbursements
Medicare Part D and Medicaid programs have negotiated discounts and rebates, lowering effective costs. However, the list prices set by manufacturers often influence downstream pricing trends.
Market Challenges and Risks
- Biosimilar Entry: The potential for biosimilars to enter the MS biologics space by 2025-2027 poses a significant threat to Ocrevus pricing. Existing biosimilar development pipelines targeting ocrelizumab threaten to increase price competition.
- Cost Containment Measures: Payers are increasingly adopting formulary restrictions, prior authorizations, and step therapy protocols to control expenditures, exerting downward pressure on prices.
- Regulatory and Patent Challenges: Patent litigations and potential patent extensions could influence the timing of biosimilar entry.
Price Projections (2023–2028)
| Year | Estimated Price Range (per 300 mg infusion) | Notes |
|---|---|---|
| 2023 | $7,500 – $7,750 | Current stabilized prices |
| 2024 | $7,250 – $7,700 | Slight downward trend due to payer negotiations |
| 2025 | $6,500 – $7,250 | Biosimilar competition begins to impact prices |
| 2026 | $6,000 – $7,000 | Increased biosimilar market penetration |
| 2027 | $5,500 – $6,750 | Expanded biosimilar options, further price reduction |
| 2028 | $5,000 – $6,500 | Market stabilization at lower price levels |
Note: These projections assume FDA approval and commercialization of biosimilars and a gradual adaptation of payer policies toward cost-containment.
Conclusion
The Ocrevus (NDC 58151-0158) market remains robust due to its clinical efficacy and strong position within MS therapeutics. However, the trajectory of the drug's pricing is increasingly influenced by biosimilar competition, payer negotiations, and healthcare policy shifts. While list prices are expected to decline modestly over the next five years, the actual net prices may vary significantly based on regional negotiations, rebates, and formulary placements.
Strategic considerations for stakeholders include monitoring biosimilar development, engaging in payer negotiations proactively, and evaluating patient access strategies to optimize market share amid evolving competitive pressures.
Key Takeaways
- The current list price for Ocrevus remains around $7,500 per 300 mg infusion, with limited fluctuations driven by market factors.
- Biosimilar competition, anticipated by mid-2020s, will be the primary driver of price reductions, potentially decreasing net prices by 25-30% over five years.
- Payer strategies, including formulary management and negotiated rebates, significantly influence actual transaction prices.
- Growing global MS prevalence supports sustained demand, but pricing pressures necessitate innovation in market positioning.
- Stakeholders must prepare for increased bio-equivalence products and evolving reimbursement landscapes to maintain profitability.
FAQs
1. How will biosimilar entry impact Ocrevus pricing?
Biosimilar entry is projected to decrease list prices by introducing alternative options, fostering competitive pricing, and reducing net reimbursement costs. However, patent litigations and regulatory timelines can delay biosimilar availability, leading to a temporary stabilization of prices.
2. What are the primary factors influencing Ocrevus’s market share growth?
Efficacy profile, safety data, formulary placement, patient access programs, and physician familiarity govern market share. Regulatory approvals for additional indications also help capture broader patient populations.
3. Are there any upcoming patent expirations for Ocrevus?
As of the current analysis, Ocrevus’s fundamental patents extend through 2027–2028. Patent expirations will likely coincide with biosimilar approvals and market introductions, catalyzing price reductions.
4. What geographic markets are most promising for Ocrevus?
While the U.S. remains the largest single market, Europe and Asia-Pacific are emerging territories with expanding MS diagnoses. Price dynamics and reimbursement policies vary regionally, influencing market penetration.
5. How can pharmaceutical companies mitigate downward pricing pressures?
Strategies include innovation in drug formulations, expanding indications, implementing value-based pricing models, strengthening patient adherence programs, and engaging in strategic partnerships with payers to secure preferred formulary status.
References
- Multiple Sclerosis Society. (2022). "Global MS Statistics."
- Fortune Business Insights. (2022). "Global Multiple Sclerosis Market."
- FDA. (2017). "Ocrevus (Ocrelizumab) Approval."
- IQVIA. (2022). "Pharmaceutical Pricing and Reimbursement Data."
- Gene Therapy and Biologics Market Reports. (2023). "Biosimilar Pipeline and Market Impact."
More… ↓
